Summary & Overview
HCPCS Level II C9302: Injection, zanidatamab-hrii, 2 mg
HCPCS Level II code C9302 designates a 2 mg unit of zanidatamab-hrii for injection, a specialty biologic used in oncology care. As a HCPCS Level II product code, C9302 facilitates billing and reimbursement for the drug supply component when zanidatamab-hrii is administered in clinical settings. Nationally, precise identification of this code matters for payer coverage determinations, drug utilization tracking, and facility reimbursement workflows.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and the clinical service type. The publication summarizes payer coverage landscape and common billing modifiers used with HCPCS drug codes, and it highlights operational considerations relevant to infusion centers and hospital outpatient departments.
This piece provides benchmarks and policy context relevant to providers, billing teams, and revenue cycle managers seeking clarity on coding for zanidatamab-hrii. It also outlines items often included in payer reviews such as drug unit reporting, documentation expectations, and the relationship between HCPCS drug codes and administration services. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code C9302 represents Injection, zanidatamab-hrii, 2 mg. This code describes a single unit of a specialty oncology biologic supplied for parenteral administration.
Service type: Injectable biologic therapy
Typical site of service: Outpatient infusion center or hospital outpatient department
Clinical & Coding Specifications
Clinical Context
A patient with advanced or metastatic HER2-expressing solid tumor (e.g., biliary tract carcinoma or other indicated malignancy) presents to the oncology infusion center for administration of a targeted monoclonal antibody therapy. The service billed as C9302 represents the drug product dose of zanidatamab-hrii, measured per 2 mg increment. Typical workflow: oncology provider documents indication, treatment plan, and dose calculation in the electronic medical record; pharmacy prepares the calculated vial(s) and verifies concentration and compatibility; an infusion nurse performs site verification, pre-medication assessment, and intravenous access; the drug is administered per protocol in the ambulatory infusion suite or hospital outpatient infusion department; nursing documents lot number, dose administered (in mg), infusion start/stop times, and relevant observations. Billing staff link the administered units of C9302 to the patient’s medical record, append appropriate procedure or facility modifiers as indicated, and submit claims to payors such as Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required to administer or manage therapy is substantially greater than typical (Medical documentation must support). |